Pulmonary hypertension in idiopathic pulmonary fibrosis

Pulmonary Arterial Hypertension and Interstitial Lung Diseases: A Clinical Guide

Volumn , Issue , 2009, Pages 177-194

  Martinez, Fernando J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649418211     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60327-074-8_9     Document Type: Chapter

References (61)

1. Noth I, Martinez F. Recent advances in idiopathic pulmonary fibrosis. Chest 2007;132:637-650.
2. Flaherty K, Rei A, Murray S, Fraley C, Colby T, Travis W, Lama V, Kazerooni E, Gross B, Toews G, Martinez F. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology six-minute-walk test. Am J Respir Crit Care Med 2006;174:803-809.
3. Gay S, Kazerooni E, Toews G, Lynch J III, Gross B, Cascade P, Spizarny D, Flint A, Schork M, Whyte R, Popovich J, Hyzy R, Martinez F. Idiopathic pulmonary fibrosis. Predicting response to therapy survival. Am J Respir Crit Care Med 1998;157:1063-1072.
4. Lynch D, Godwin J, Safrin S, Starko K, Hormel P, Brown K, Raghu G, King T Jr, Bradford W, Schwartz D, Webb W, for the Idiopathic Pulmonary Fibrosis Study Group. High-resolution computed tomography in idiopathic pulmonary fibrosis. Diagnosis prognosis. Am J Respir Crit Care Med 2005;172:488-493.
5. Collard H, King T, Jr, Bartelson B, Vourlekis J, Schwarz M, Brown K. Changes in clinical physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-542.
6. Latsi P, Du Bois R, Nicholson A, Colby T, Bisirtzoglou D, Nikolapoulou A, Veeraraghavan S, Hansell D, Wells A. Fibrotic idiopathic interstitial pneumonia. The prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531-537.
7. Jegal Y, Kim D, Shim T, Lim C, Lee S, Koh Y, Kim WS, Kim WD, Lee J, Travis W, Kitaichi M, Colby T. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2003;171:639-644.
8. Martinez F, Safrin S, Weycker D, Starko K, Bradford W, King T Jr, Flaherty K, Schwartz D, Noble P, Raghu G, Brown K, for the IPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Int Med 2005;142:963-967.
9. King T Jr., Safrin S, Starko K, Brown K, Noble P, Raghu G, Schwartz D. Analyses of efficacy end points in a controlled trial of interferon-γ1b for idiopathic pulmonary fibrosis. Chest 2005;127:171-177.
10. Martinez F. Idiopathic interstitial pneumonias. Usual interstitial pneumonia versus nonspecific interstitial pneumonia. Proc Am Thorac Soc 2006;3:81-95.
11. Lettieri C, Nathan S, Barnett S, Ahmad S, Shorr A. Prevalence outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006;129:746-752.
12. Nadrous H, Pellikka P, Krowka M, Swanson K, Chaowalit N, Decker P, Ryu J. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005;128:2393-2399.
13. Hamada K, Nagai S, Tanaka S, Ha T, Mishima M, Kitaichi M, Izumi T. Significance of pulmonary arterial pressure diffusing capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007;131:650-656.
14. Vizza C, Lynch J, Ochoa L, Richardson G, Trulock E. Right left ventricular dysfunction in patients with severe pulmonary disease. Chest 1998;113:576-583.
15. Agarwal R, Gupta D, Verma J, Aggarwal A, Jindal S. Noninvasive estimation of clinically asymptomatic pulmonary hypertension in idiopathic pulmonary fibrosis. Indian J Chest Dis Allied Sci 2005;47:267-271.
16. Cottin V, Nunes H, Brillet P, Delaval P, Devouassaoux G, Tillie-Leblond I, Israel-Biet D, Court-Fortune I, Valeyre D, Cordier J, Groupe d'Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis emphysema: a distinct underrecognized entity. Eur Respir J 2005;26:586-593.
17. Grubstein A, Bendeyan D, Schactman I, Cohen M, Shitrit D, Kramer M. Concomitant upperlobe bullous emphysema, lower-lobe interstitial fibrosis pulmonary hypertension in heavy smokers: report of eight cases review of the literature. Respir Med 2005;99:948-954.
18. Arcasoy S, Christie J, Ferrari V, Sutton M, Zisman D, Blumenthal N, Pochettino A, Kotloff R. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003;167:735-740.
19. Zisman D, Ross D, Belperio J, Saggar R, Lynch J III, Ardehali A, Karlamangia A. Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2007;101:2153-2159
20. Shorr A, Wainright J, Cors C, Lettieri C, Nathan S. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplantation. Eur Respir J 2007;30:715-721.
21. Yang Y, Johnson C, Hoffman K, Mulligan M, Spada C, Raghu G. Pulmonary arterial hypertension in patients with idiopathic pulmonary fibrosis when listed for lung transplantation (LT) at LT. Proc Am Thorac Soc 2006;3:A369.
22. Nathan S, Shlobin O, Ahmad S, Koch J, Barnett S, Ad N, Burton N, Leslie K. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 2008;76:288-94.
23. Leuchte H, Baumgartner R, Nounou M, Vogeser M, Neurohr C, Trautniz M, Behr J. Brain natriuretic is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006;173:744-750.
24. Leuchte H, Neurohr C, Baumgartner R, Holzapfel M, Gierhl W, Vogeser M, Behr J. Brain natriuretic peptide exercise capacity in lung fibrosis pulmonary hypertension. Am J Respir Crit Care Med 2004;170:360-365.
25. Zisman D, Karlamangia A, Kawut S, Shlobin O, Saggar R, Ross D, Schwarz M, Belperio J, Ardehali A, Lynch J III, Nathan S. Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2008;133:640-645.
26. Zisman D, Karlamangia A, Ross D, Keane M, Belperio J, Saggar R, Lynch J III, Ardehali A, Goldin J. High-resolution chest computed tomography findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2007;132:773-779.
27. Nathan S, Noble P, Tuder R. Idiopathic pulmonary fibrosis pulmonary hypertension. Connecting the dots. Am J Respir Crit Care Med 2007;175:875-880.
28. Weitzenblum E, Chaouat A. Hypoxic pulmonary hypertension in man: what minimum daily duration of hypoxaemia is required? Eur Respir J 2001;18:251-253.
29. Weitzenblum E. Chronic cor pulmonale. Heart 2003;89:225-230.
30. Tzouvelekis A, Harokopos V, Paparountas T, Oikonomou N, Chatziioannou A, Vilaras G, Tsiambas E, Karameris A, Bouros D, Aidinis V. Pulmonary fibrosis comparative expression profiling suggests key role of hypoxia inducible factor 1a. Am J Respir Crit Care Med 2007;176:1108-1119.
31. Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M, Sasano H, Kondo T, Nukiwa T. Heterogenous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004;169:1203-1208.
32. Cosgrove G, Brown K, Schiemann W, Serls A, Parr J, M Geraci, Schwarz M, Cool C, Worthen G. Pigment epithelial-derived factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004;170:242-251.
33. Simler N, Brenchley P, Horrocks A, Greaves S, Hasleton P, Egan J. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 2004;59:581-585.
34. Renzoni E, Walsh D, Salmon M, Wells A, Sestini P, Nicholson A, Veeraraghavan S, Bishop A, Romanksa H, Pantelidis P, Black C, Du Bois R. Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med 2003;167:438-443.
35. Colombat M, Mal H, Groussard O, Capron F, Thabut G, Jebrak G, Brugiere O, Dauriat G, Castier Y, Leseche G, Fournier M. Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: histopathologic study on lung explant specimens correlations with pulmonary hemodynamics. Human Pathol 2007;38:60-65.
36. Gagermeier J, Dauber J, Yousem S, Gibson K, Kaminski N. Abnormal vascular phenotypes in patients with idiopathic pulmonary fibrosis secondary pulmonary hypertension. Chest 2005;128:601S.
37. Charbeneau R, Peters-Golden M. Eicosanoids: mediators therapeutic targets in fibrotic lung disease. Clin Sci (Lond) 2005;108:479-491.
38. Budhiraja R, Tuder R, Hassoun P. Endothelial dysfunction in pulmonary hypertension. Circulation 2004;109:159-65.
39. Giaid A, Michel R, Stewart D, Sheppard M, Corrin B, Hamid Q. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993;341:1550-1554.
40. Saleh D, Furukawa K, Tsao M, Maghazachi A, Corrin B, Yanagisawa M, Barnes P, Giaid A. Elevated expression of endothelin-1 endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am J Respir Cell Mol Biol 1997;16:187-193.
41. Trakada G, Spiropoulos K. Arterial endothelin-1 in interstitial lung disease patients with pulmonary hypertension. Monaldi Arch Chest Dis 2001;56:379-383.
42. Douglas W, Ryu J, Schroeder D. Idiopathic pulmonary fibrosis. Impact of oxygen colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000;161:1172-1178.
43. Crockett A, Cranston J, Antic N. Domiciliary oxygen for interstitial lung disease. Cochrane Database of Syst Rev 2001; (3): CD002883.
44. Carpagnano G, Kharitonov S, Foschino-Barbaro M, Resta O, Gramiccioni E, Barnes P. Supplementary oxygen in healthy subjects those with COPD increases oxidative stress airway inflammation. Thorax 2004;59:1016-1019.
45. Barbaro M, Serviddio G, Resta O, Rollo T, Tamborra R, Carpagnano G, Vendemiale G, Altomare E. Oxygen therapy at low flow rates causes oxidative stress in chronic obstructive pulmonary disease: Prevention by N-acetyl cysteine. Free Radical Res 2005;39:1111-1118.
46. Kinnula V, Fattman C, Tan R, Oury T. Oxidative stress in pulmonary fibrosis. A possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005;172:417-422.
47. Yoshida M, Taguchi O, Gabazza E, Yasui H, Kobayashi T, Kobayashi H, Maruyama K, Adachi Y. The effect of low-dose inhalation of nitric oxide in patients with pulmonary fibrosis. Eur Respir J 1997;10:2051-2054.
48. Yung G, Kriett J, Jamieson S, Johnson F, Newhart J, Kinninger K, Channick R. Outpatient inhaled nitric oxide in a patient with idiopathic pulmonary fibrosis: a bridge to lung transplantation. J Heart Lung Transplant 2001;20:1224-1227.
49. Olschewski H, Ghofrani H, Walmrath D, Schermuly R, Temmesfeld- Wollbrück B, Grimminger F, Seeger W. Inhaled prostacyclin iloprost in severe pulmonary hypertension secondary to lung fibrosis [in German]. Am J Respir Crit Care Med 1999;160:600-607.
50. Ghofrani H, Wiedemann R, Rose F, Schermuly R, Olschewski H, Weissman N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895-900.
51. Madden B, Allenby M, Loke T, Sheth A. A potential role for sildanefil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vasc Pharmacol 2006;44:372-376.
52. Madden B, Sheth A, Wilde M, Ong Y. Does sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung cardiac disease? Vasc Pharmacol 2007;47:184-188.
53. Collard H, Anstrom K, Schwarz M, Zisman D. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007;131:897-899.
54. Charman S, Sharples L, McNeil K, Wallwork J. Assessment of survival benefit after lung transplantation by patient diagnosis. J Heart Lung Transplant 2002;21:226-232.
55. De Meester J, Smits JM, Persijn GG, Haverich A. Listing for lung transplantation: life expectancy transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience. J Heart Lung Transplant 2001;20:518-524.
56. Thabut G, Mal H, Castier Y, Groussard O, Brugiere O, Marrash-Chahla R, Leseche G, Fournier M. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 2003;126:469-475.
57. Whelan T, Dunitz J, Kelly R, Edwards L, Herrington C, Hertz M, Dahlberg P. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 2005;24:1269-1274.
58. Huerd S, Hodges T, Grover F, Mault J, Mitchell M, Campbell D, Aziz S, Chetham P, Torres F, Zamora M. Secondary pulmonary hypertension does not adversely affect outcome after single lung transplantation. J Thorac Cardiovasc Surg 2000;119:458-465.
59. Conte J, Borja M, Patel C, Yang S, Jhaveri R, Orens J. Lung transplantation for primary secondary pulmonary hypertension. Ann Thorac Surg 2001;72:1673-1680.
60. Egan T, Kotloff R. Pro/Con debate: lung allocation should be based on medical urgency transplant survival not on waiting time. Chest 2005;128:407-415.
61. Lingaraju R, Blumenthal N, Kotloff R, Christie J, Ahya V, Sager J, Pochettino A, Hadjiliadis D. Effects of lung allocation score on waiting list rankings transplant procedures. J Heart Lung Transplant 2006;25:1167-1170.